Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93903Research ArticlePrimenenie mukoliticheskikh preparatov pri bronkhoobstruktivnom sindromeZykovK. A-TkhorzhevskayaT. V-SokolovE. I-151120131511172128122021Copyright © 2013, Consilium Medicum2013бронхообструктивный синдромхроническая обструктивная болезнь легкихмуколитические препараты[Овчаренко С. И. Бронхообструктивный синдром в практике врача - терапевта. Справочник поликлинического врача. 2011; 2: 38–41.][Braman S.S. Chronic cough due to chronic bronchitis: ACCP evidence - based clinical practice guidelines. Chest 2006; 129 (Suppl. 1): 104S–115S.][Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (updated 2013). http://www.ginasthma.org][Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd.org/][Han M.K, Agusti A, Calverley P.M. Chronic Obstructive Pulmonary Disease Phenotypes. The Future of COPD. Am J Respir Crit Care Med; 2010; 182: 598–604.][Miravitlles M, Soler-Cataluña J.J, Calle M et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol 2012; 48 (7): 247–57.][Miravitlles M, Soler-Cataluña J.J, Calle M, Soriano J.B. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 2013; 41 (6): 1252–6.][Malerba M, Ponticiello A, Radaeli A et al. Effect of twelve - months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double - blind, randomized, multicenter, placebo - controlled study (the AMETHIST Trial). Pulm Pharmacol Ther 2004; 17 (1): 27–34.][Jуnsson J.S. Acute bronchitis and clinicaloutcome three years later: prospectivecohort study. BMJ 1998; 317: 1433.][Hallett J.S. Recurrent acute bronchitis: the association with undiagnosed bronchial asthma. Ann Allergy 1985; 55: 568–70.][Melbye H, Kongerud J, Vorland L. Reversible airflow limitation in adults with respiratory infection. Eur Respir J 1994; 7: 1239–45.][Balsamo R, Lanata L, Egan C.G. Mucoactive drugs. Eur Respir Rev 2010; 19 (116): 127–33.][Yamaya M, Nishimura H, Nadine L.K et al. Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Arch Pharm Res 2013.][Allegra R. Is there a place for oral mucolytics in the prevention of LRTI? ERS annual Congress 2009. http://www.ersnet.org][Schulz M, Hämmerlein A, Hinkel U et al. Safety and usage pattern of an over - the - counter ambroxol cough syrup: a community pharmacy - based cohort study. Int J Clin Pharmacol Ther 2006; 44 (9): 409–21.][Macfarlane J, Holmes W, Gard P et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001; 56 (2): 109–14.][Poole P, Black P.N, Cates C.J. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 8: CD001287.][Decramer M, Ruttenvan Molken M, Dekhuijzen P.N et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo - controlled trial. Lancet 2005; 365 (9470): 1552–60.][Zheng J.P, Kang J, Huang S.G et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo - controlled study. Lancet 2008; 371 (9629): 2013–8.]